Bicocca Open Archive

Logo unimib boa
BIDOLI, PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6158
EU - Europa 1642
AS - Asia 396
AF - Africa 7
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 2
SA - Sud America 2
Totale 8210
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6059
IT - Italia 414
SE - Svezia 396
DE - Germania 350
CN - Cina 269
IE - Irlanda 129
UA - Ucraina 97
CA - Canada 95
GB - Regno Unito 83
VN - Vietnam 44
DK - Danimarca 37
AT - Austria 35
IN - India 28
TR - Turchia 25
BE - Belgio 23
FR - Francia 20
RU - Federazione Russa 19
FI - Finlandia 16
JP - Giappone 9
IR - Iran 8
NL - Olanda 8
PL - Polonia 7
HK - Hong Kong 4
MU - Mauritius 4
AU - Australia 2
BD - Bangladesh 2
BG - Bulgaria 2
EU - Europa 2
ID - Indonesia 2
MX - Messico 2
RO - Romania 2
SA - Arabia Saudita 2
TW - Taiwan 2
BR - Brasile 1
CL - Cile 1
CZ - Repubblica Ceca 1
EG - Egitto 1
ES - Italia 1
GR - Grecia 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
PA - Panama 1
PK - Pakistan 1
PR - Porto Rico 1
SC - Seychelles 1
SI - Slovenia 1
Totale 8210
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1350
Fairfield 862
Woodbridge 495
Wilmington 436
Ashburn 395
Chandler 376
Seattle 363
Cambridge 325
Houston 325
Frankfurt am Main 267
Princeton 250
Jacksonville 169
Dublin 129
Altamura 124
Lawrence 119
Beijing 83
Milan 83
San Diego 70
Dearborn 66
Toronto 46
Andover 45
Vienna 33
Nanjing 30
Guangzhou 28
Dong Ket 26
Ottawa 25
Falls Church 24
Brussels 23
Hangzhou 21
London 21
Norwalk 18
Tianjin 14
Hebei 13
Lachine 13
Redmond 13
Jinan 12
Torre Del Greco 12
Rome 10
Shanghai 9
Zhengzhou 9
Nanchang 8
Chicago 7
Edmonton 7
Fremont 7
Mountain View 6
Shenyang 6
Torino 6
Carignano 5
Jiaxing 5
Lissone 5
Lodz 5
Mumbai 5
Ningbo 5
Perugia 5
Phoenix 5
San Mateo 5
Desio 4
Huizen 4
Kunming 4
Laurel 4
Bergamo 3
Broni 3
Changsha 3
Hefei 3
Kocaeli 3
Los Angeles 3
Montréal 3
Munich 3
Philadelphia 3
Sacramento 3
Seregno 3
Tokyo 3
Aci Catena 2
Amsterdam 2
Annone di Brianza 2
Atlanta 2
Bari 2
Bedford 2
Central District 2
Como 2
Gragnano 2
Helsinki 2
Istanbul 2
Jakarta 2
Kiev 2
Krakow 2
Lanzhou 2
Leawood 2
Ludhiana 2
Monte Urano 2
New York 2
Nishinomiya 2
Novara 2
Oklahoma City 2
Ottaviano 2
Reggio Emilia 2
Reggio Nell'emilia 2
Segrate 2
Taipei 2
Trumbull 2
Totale 6932
Salva come PNG Salva come JPEG
Nome #
Metronomic combination of Vinorelbine and 5Fluorouracil is able to inhibit triple-negative breast cancer cells. Results from the proof-of-concept VICTOR-0 study. 255
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib 216
Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity 213
Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20) 211
Validation of the Italian version of the full and abbreviated Trust in Oncologist Scale 210
Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS) 199
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 197
The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings 191
New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma 157
Correspondence between neurophysiological and clinical measurements of chemotherapy-induced peripheral neuropathy: secondary analysis of data from the CI-PeriNoms study 149
C-arm cone-beam CT-guided transthoracic lung core needle biopsy as a standard diagnostic tool 148
Neuropathic pain and chemotherapy-induced peripheral neurotoxicity: the issue 146
"Why my parent is ill?" A specific, multidisciplinary intervention to enhance comunication to cancer patients' children 140
Neuroprotectant agents against oxaliplatin induced neurotoxicity: lackings, facts and future prospective 138
Rasch-Transformed Total Neuropathy Score clinical version (RT-TNSc©) in patients with chemotherapy-induced peripheral neuropathy 136
Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools 136
A Longitudinal Study on Oxaliplatin Induced Peripheral Neuropathy – Incidence and Facts About the “Real Life” Population And Actual Dose 132
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer 124
Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial 123
Liquid biopsy testing can improve selection of advanced non-small-cell lung cancer patients to rechallenge with gefitinib 108
Dorsal sural nerve conduction study in the assessment of oxaliplatin induced peripheral neuropathy 107
Normalization of the light/dark rhythm of melatonin after prolonged subcutaneous administration of interleukin‐2 in advanced small cell lung cancer patients 107
Peritoneal carcinomatosis in non-small-cell lung cancer: retrospective multicentric analysis and literature review 106
Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis 104
Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population 101
Association of systemic inflammation index and body mass index with survival in patients with renal cell cancer treated with nivolumab 99
Vanishing bile duct syndrome following pembrolizumab infusion: case report and review of the literature 99
Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer 97
Major issue in chemotherapy-induced peripheral neuropathy (cipn): lack of standardized measurement scales. ciperinoms study: validity and reliability in cipn assessment 96
Khorana score and thromboembolic risk in stage II–III colorectal cancer patients: a post hoc analysis from the adjuvant TOSCA trial 94
When progressive dysphagia could be related to an “old friend” – a case report 93
Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer 81
Novel cytotoxic chemotherapies in small cell lung carcinoma 80
Thymus neuroendocrine tumors with CTNNB1 gene mutations, disarrayed ß-catenin expression, and dual intra-tumor Ki-67 labeling index compartmentalization challenge the concept of secondary high-grade neuroendocrine tumor: a paradigm shift 78
Disseminated intravascular coagulation in advanced lung adenocarcinoma during first-line pembrolizumab 70
High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases 70
Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial 69
Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations 69
Tumor response and estrogen suppression in breast cancer patients treated with aromatase inhibitors 69
Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged ≥ 75 Years With Non–small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective Study 68
Esophageal squamous cell carcinoma: MRI evaluation of mediastinum 67
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme 66
Drugs ten years later: epirubicin 65
Gemcitabine plus vinorelbine as first-line chemotherapy in advanced nonsmall cell lung carcinoma a phase II trial 63
Malignant mesothelioma in subjects with Marfan's syndrome and Ehlers-Danlos syndrome: only an apparent association? 62
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): An open-label, randomised, controlled phase 3 trial 58
Efficacy and Safety of the All-Oral Schedule of Metronomic Vinorelbine and Capecitabine in Locally Advanced or Metastatic Breast Cancer Patients: The Phase I-II VICTOR-1 Study 58
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer 58
Detection of overexpressed and phosphorylated wild-type kit receptor in surgical specimens of small cell lung cancer 55
Pilot study with cisplatin, ifosfamide, and etoposide in advanced non-small-cell lung carcinoma 55
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study 53
Second-line erlotinib or intermittent erlotinib plus docetaxel in male ex-smokers with squamous NSCLC: The TALISMAN randomized trial 53
Phase I study of escalating doses of oxaliplatin in combination with fixed dose gemcitabine in patients with non-small cell lung cancer 53
Nutritional support in patients with cancer of the esophagus: impact on nutritional status, patient compliance to therapy, and survival 53
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial 53
Molecular and immune biomarkers for cutaneous melanoma: Current status and future prospects 53
Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study 53
Gene product immunophenotyping of neuroendocrine lung tumors. No linking evidence between carcinoids and small-cell lung carcinomas suggested by multivariate statistical analysis 52
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients 52
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): A multicentre, double-blind, randomised phase 3 trial 51
Surgical resection in the treatment of stages I-II of small cell lung carcinoma (SCLC) 51
Focus on nivolumab in NSCLC 51
Chronic effects of subcutaneous interleukin-2 therapy on soluble interleukin-2 receptors in advanced small cell lung cancer 50
The estrogen suppression after sequential treatment with formestane in advanced breast cancer patients 49
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial 49
A summary of the Milan experience with multimodality therapies in patients with small cell lung cancer: Attempts to improve long-term outcome 48
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial 48
Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First-Line Therapy in Patients with Extensive-Disease Small Cell Lung Cancer 48
Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer 48
Oxaliplatin doublets in non-small cell lung cancer: A literature review 47
Induction chemotherapy with carboplatin/paclitaxel followed by surgery or standard radiotherapy and concurrent daily low-dose cisplatin for locally advanced non-small cell lung cancer (NSCLC) 47
Antiemetic activity of metoclopramide versus alizapride during cancer chemotherapy 47
Prognosis after nonradical resections for small cell lung carcinoma (SCLC) 46
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma 46
Pilot study with adriamycin and ifosfamide in small cell lung cancer 46
Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial) 45
Treatment with gefitinib in elderly patients or patients with poor performance status (PS) affected with non small cell lung carcinoma (NSCLC) 45
Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer 44
FHIT and p53 status and response to platinum-based treatment in advanced non-small cell lung cancer 44
Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX 44
A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin 44
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: Phase III randomized LUX-Lung 5 trial 43
Ten-year survival with chemotherapy and radiotherapy in patients with squamous cell carcinoma of the esophagus 43
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial 43
Long-term and low-grade safety results of a phase III study (PARAMOUNT): maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer 43
Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer 43
Comparative in vitro sensitivity of human cholangiocarcinoma and colon adenocarcinoma cells to anticancer agents 43
Randomized phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian Trials in Medical Oncology study 42
Phase III trial comparing 3-6months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: Safety and compliance in the TOSCA trial 42
Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study 42
Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset 42
Esophageal carcinoma: radiochemotherapy 41
Isolated cardiac metastasis from squamous cell esophageal cancer 41
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial 41
PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer 41
EAGLES study: First-line bevacizumab in combination with chemotherapy in elderly patients with advanced, metastatic, non-squamous non-small cell lung cancer 41
Efficacy and safety of vinorelbine-capecitabine oral metronomic combinaton in elderly metastatc breast cancer patents: VICTOR-1 study 40
NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial 40
Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study 40
Exposure–response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer 40
Totale 7997
Salva come PNG Salva come JPEG
Categoria #
all - tutte 19865
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19865
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/20189 0000 00 00 0009
2018/2019370 2814123 1025 3023 29616471
2019/20202199 77484148 66107 143685 41225323980
2020/20212601 135136327241 138188 295324 221221181194
2021/20221242 11015616071 4088 7962 675496259
2022/20231910 275646129135 84306 38100 13623362
Totale 8804